- Key facts & figures
- Sanofi share
- Analysts / Vara Consensus
- News & publications
- Events & presentations
- Corporate governance
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- US investors
- Regulated information in France
Investor Relations Awards
- Media Releases
- Image Library
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Our company
- R&D innovation
- Our Products
- Our approach
- Improving access to healthcare
- Working together
- Acting ethically
- Preserving the environment
Ensuring sustainable growth
Our guidance is established following information, assumptions and intentions that may be, completely or partially, based on assumptions and decisions of the Sanofi management that could evolve or change in the future.
2015 guidance announced on October 29, 2015
Sanofi reaffirms that it expects 2015 Business EPS to be stable to slightly growing versus 2014* at constant average exchange rates, barring unforeseen major adverse events.
In addition, the positive currency impact on 2015 full-year business EPS is estimated to be between 6% and 8%, under the assumption that exchange rates remain stable in fourth quarter at the average rates of September 2015.
2015 guidance announced on July 30, 2015
The performance of the second quarter is in line with the full year guidance announced on February 5, 2015. Sanofi expects 2015 Business EPS to be stable to slightly growing versus 2014* at constant average exchange rates, barring major unforeseen adverse events.
In addition, the positive currency impact on 2015 full-year business EPS is estimated to be approximately +10%, under the assumption that exchange rates remain stable in the following two quarters at the average rates of June 2015.
2015 guidance announced on April 30, 2015
Sanofi continues to expect 2015 Business EPS to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events*.
In addition, the positive currency impact on 2015 full-year business EPS is estimated to be approximately +12%, under the assumption that exchange rates remain stable in the following three quarters at the average rates of March 2015.
2015 guidance announced on February 5, 2015
Taking into account the outlook for U.S. Diabetes as well as new product launches and late stage pipeline development, 2015 Business EPS is expected to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events*.
Applying December 31, 2014 exchange rates to this full-year 2015 guidance, the additional positive currency impact on 2015 business EPS is estimated to be between 4% and 5%.
Cautionary statement regarding forward-looking statements
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding, as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Further information on risk factors:
- Group sites
- Legal Notice
- Cookies policy
- Cookies settings
- Corporate Code of Ethics